Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer - NCT00217737-54601A(Clinical Trial 307675)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
La Crosse |
|
State:
|
|
WI |
| Zip Code: |
|
54601 |
| Conditions: |
|
Colorectal Cancer |
| Purpose: |
|
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab
may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving
combination chemotherapy together with bevacizumab after surgery may kill any remaining
tumor cells or prevent the cancer from coming back. Sometimes, after surgery, the tumor may
not need additional treatment until it progresses. In this case, observation may be
sufficient. It is not yet known whether giving combination chemotherapy together with
bevacizumab is more effective than combination chemotherapy alone or observation only in
treating colon cancer.
PURPOSE: This randomized phase III trial is studying oxaliplatin, leucovorin, fluorouracil,
and bevacizumab to see how well they work compared to oxaliplatin, leucovorin, and
fluorouracil or observation only in treating patients who have undergone surgery for stage
II colon cancer.
|
| Study summary: |
|
OBJECTIVES:
Primary
- Compare the 3-year disease-free survival of patients with resected stage II colon
cancer at high risk for recurrence treated with oxaliplatin, leucovorin calcium, and
fluorouracil with vs without bevacizumab.
Secondary
- Compare the overall survival of patients treated with these regimens.
- Compare the toxicity profiles of these regimens in these patients.
- Correlate tumor biologic characteristics with survival of patients treated with these
regimens.
OUTLINE: This is a randomized study. Patients are stratified according to disease stage (IIA
vs IIB) and microsatellite stability (MSS) (stable vs low-grade instability [MSI-L]).
Patients with disease that is at high risk for microsatellite instability (MSI) and loss of
heterozygosity (LOH) at chromosome 18q are randomized to 1 of 2 treatment arms (arms I and
II). Patients with disease that is at low risk for MSI and 18q LOH are assigned to arm III.
- Arm I: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2
hours on day 1. Patients also receive fluorouracil IV bolus followed by fluorouracil IV
continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 12
courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in arm I
and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks for 12
courses in the absence of disease progression or unacceptable toxicity. Patients then
receive bevacizumab alone for 12 additional courses in the absence of disease
progression or unacceptable toxicity.
- Arm III: Patients undergo observation only. Patients are followed every 3 months for
1-2 years, every 6 months for 3 years, and then annually for up to 10 years from study
entry.
PROJECTED ACCRUAL: A total of 3,610 patients will be accrued for this study within 5.8
years. |
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the colon
- Stage II disease (pT3, pT4a-b, N0, M0)
- At least 8 lymph nodes must have been evaluated
- Meets 1 of the following criteria:
- High risk for microsatellite instability (MSI) and loss of heterozygosity (LOH)
at chromosome 18q
- Microsatellite stable (MSS) with 18q LOH
- MSI-low grade (MSI-L) with 18q LOH
- Low risk for MSI and 18q LOH
- MSS with retention of 18q alleles
- MSI-L with retention of 18q alleles
- MSI-high grade (MSI-H) with retention of 18q alleles
- MSI-H without retention of 18q alleles
- MSI-H with 18q status uninformative
- Distal extent of tumor must be ≥ 12 cm from the anal verge by endoscopy or surgical
examination
- If tumor is located beyond sigmoid colon and centimeter distance is unavailable,
include anatomic region of the colon (e.g., right colon, transverse colon,
hepatic flexure, descending colon, or cecum)
- Has undergone surgical resection of the tumor between the past 28-60 days
- Must have had a complete resection (R0 resection)
- No history of isolated, distant, or noncontiguous intra-abdominal metastases
- Patients with synchronous tumors or appendiceal tumors are ineligible
- Hereditary non-polyposis colorectal cancer allowed
- Paraffin-embedded tumor specimen (one with normal mucosa and one from the resection
tumor) available
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- Absolute granulocyte count ≥ 1,500/mm^3*
- Platelet count ≥ 100,000/mm^3*
- No significant bleeding unrelated to tumor within the past 6 months* NOTE: *For
patients with high-risk disease only
Hepatic
- Bilirubin normal (unless due to Gilbert's disease or similar syndrome)*
- Alkaline phosphatase (AP) < 2.5 times upper limit of normal (ULN)*
- AST < 1.5 times ULN*
- PT INR > 1.5* allowed provided the following criteria are met:
- Patient is on full-dose anticoagulants
- INR in range (usually 2-3) on a stable dose of warfarin or low molecular weight
heparin
- No active bleeding or pathological condition associated with a high risk of
bleeding unrelated to primary colon tumor
- No systemic hepatic disease* NOTE: *For patients with high-risk disease only
Renal
- Creatinine ≤ 1.5 times ULN*
- Urine protein:creatinine ratio < 1.0* OR
- Urine protein < 1 gm on 24-hour urine collection*
- No systemic renal disease* NOTE: *For patients with high-risk disease only
Cardiovascular
- History of hypertension allowed provided blood pressure < 150/90 mm Hg while on a
stable regimen of anti-hypertensive therapy*
- No New York Heart Association class III or IV cardiac disease*
- No symptomatic arrhythmia*
- No history of transient ischemic attack*
- No history of cerebrovascular accident*
- No symptomatic peripheral vascular disease*
- No arterial thromboembolic events within the past 12 months*
- No unstable angina within the past 12 months*
- No myocardial infarction within the past 12 months*
- No other systemic cardiovascular disease* NOTE: *For patients with high-risk disease
only
Other
- Not pregnant or nursing*
- Negative pregnancy test*
- Fertile patients must use effective contraception during and for 3 months after
completion of study treatment*
- No active gastroduodenal ulcer by endoscopy*
- No complete obstruction or perforation of the bowel
- No history of inflammatory bowel disease
- No prior or concurrent malignancy except for nonmelanoma skin cancer, carcinoma in
situ of the cervix, breast cancer in situ, treated non-pelvic cancer from which the
patient has been disease-free for > 5 years, or history of breast cancer (without
evidence of disease) and remain on hormonal therapy for > 5 years
- No other nonmalignant systemic disease that would preclude study compliance*
- No psychiatric or addictive disorder or other condition that would preclude study
participation*
- No serious or non-healing wound, skin ulcer, or bone fracture*
- No peripheral neuropathy ≥ grade 2*
- No significant traumatic injury within the past 4 weeks*
- No known allergy to platinum compounds NOTE: *For patients with high-risk disease
only
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- No prior radiotherapy for this cancer
Surgery
- See Disease Characteristics
- More than 28 days since prior major surgery or open biopsy*
- More than 7 days since prior core biopsy or other minor procedure except placement of
a vascular access device* NOTE: *For patients with high-risk disease only
Other
- No prior systemic therapy for this cancer NOTE: *For patients with high-risk disease
only |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
October 7, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|